UW Tests Drug For COVID-19 Complications
Clinical trial tor Ruxolitinib testing if drug can slow immune systems gone haywire.
![UW Health University Hospital, the UW–Madison Health Sciences Learning Center, and the Wisconsin Institutes for Medical Research in Madison, Wisconsin. Photo by Av9 [CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)].](https://urbanmilwaukee.com/wp-content/uploads/2020/01/1280px-UW_Health_and_UWSMPH-985x768.jpg)
UW Health University Hospital, the UW–Madison Health Sciences Learning Center, and the Wisconsin Institutes for Medical Research in Madison, Wisconsin. Photo by Av9 [CC BY-SA (https://creativecommons.org/licenses/by-sa/4.0)].
Researchers around the globe are testing potential COVID-19 treatments to not only boost a person’s immune response to the virus, but to also tamp it down when necessary.
The latter is important because when the immune system goes into overdrive for some patients infected with coronavirus, it causes what’s called a “cytokine storm,” which can be deadly. Cytokines are blood proteins that play a role in preventing the spread of harmful viruses to other cells. When there are too many cytokines, it can damage organs like lungs, making it hard to breathe.
Ruxolitinib is currently used by doctors to prevent that overreaction for bone marrow transplant patients. Researchers suspect ruxolitinib treatment may prevent or treat multi-system organ failure in patients with COVID-19.
Nugent and David Andes, principal investigator of the Phase lll trial, are working with pharmaceutical manufacturers Novartis and Incyte to test ruxolitinib in the sickest COVID-19 patients.
“I think one of the reasons this is really important is that in the absence of having anything that can really prevent COVID-19 we need to do the best we can in managing the symptoms,” said Nugent.
Researchers were able to start a Phase lll trial quickly and bypass other required steps because ruxolitinib has already been tested for safety in other conditions like graft-versus-host disease, Nugent said.
This is just one drug that researchers around Wisconsin are investigating against COVID-19.
Remdesivir has shown promise in helping patients recover faster from COVID-19. Researchers have also injected patients with plasma from those who have recovered from COVID-19 to see if it gives patient’s immune system a needed boost.
Listen to the WPR report here.
UW Tests Drug To Prevent Deadly Complication In COVID-19 Patients was originally published by Wisconsin Public Radio.
More about the Coronavirus Pandemic
- MHD Release: Milwaukee Health Department Launches COVID-19 Wastewater Testing Dashboard - City of Milwaukee Health Department - Jan 23rd, 2024
- Milwaukee County Announces New Policies Related to COVID-19 Pandemic - County Executive David Crowley - May 9th, 2023
- DHS Details End of Emergency COVID-19 Response - Wisconsin Department of Health Services - Apr 26th, 2023
- Milwaukee Health Department Announces Upcoming Changes to COVID-19 Services - City of Milwaukee Health Department - Mar 17th, 2023
- Fitzgerald Applauds Passage of COVID-19 Origin Act - U.S. Rep. Scott Fitzgerald - Mar 10th, 2023
- DHS Expands Free COVID-19 Testing Program - Wisconsin Department of Health Services - Feb 10th, 2023
- MKE County: COVID-19 Hospitalizations Rising - Graham Kilmer - Jan 16th, 2023
- Not Enough Getting Bivalent Booster Shots, State Health Officials Warn - Gaby Vinick - Dec 26th, 2022
- Nearly All Wisconsinites Age 6 Months and Older Now Eligible for Updated COVID-19 Vaccine - Wisconsin Department of Health Services - Dec 15th, 2022
- City of Milwaukee Bi-Weekly COVID-19 Update - City of Milwaukee Health Department - Dec 9th, 2022
Read more about Coronavirus Pandemic here